Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735604 | 0.89 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL7004062 | 0.89 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL7004274 | 0.89 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL715319 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL3964037 | 0.81 | ESR2 (0.74) | ESR2MAPT | |
| SCHEMBL18980759 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL17996691 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL3668278 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL718300 | 0.81 | ESR2 (0.50) | ESR2MAPTPDE4APDE4BPDE4C | |
| SCHEMBL715591 | 0.81 | MAPT (0.59) | ESR2MAPTLMNAALDH1A1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ZHEJIANG UNIVERSITY (CN) | 2022-12-20 | — | — | US | disclosed |
| CN-108299334-B | Bicyclic sulfinamide-alkene chiral ligand, and preparation method and application thereof | 成都理工大学 | 2021-06-25 | — | — | CN | disclosed |
| US-20210163514-A1 | COMPOUND OF 3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-BASED PHOSPHINE LIGAND, AND PREPARATION METHOD THEREOF | ZHEJIANG UNIVERSITY (CN) | 2021-06-03 | — | — | US | disclosed |
| CN-108659041-B | Phosphine ligand compound based on tetramethyl spiroindane skeleton, intermediate thereof, preparation method and application | 浙江大学 | 2020-04-10 | — | — | CN | disclosed |
| EP-2816040-B1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | CENTREXION THERAPEUTICS CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-108659041-A | Phosphine ligands compound and its intermediate and preparation method based on tetramethyl spiro indan skeleton and purposes | 浙江大学 | 2018-10-16 | — | — | CN | disclosed |
| US-9850206-B2 | S1P and/or ATX modulating agents | BIOGEN MA INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-20160229778-A1 | DIRECT B-ARYLATION OF CARBONYL COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-08-11 | — | — | US | disclosed |
| US-20150274663-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2015-10-01 | — | — | US | disclosed |
| US-20070123715-A1 | Method of using rhodium quinonoid catalysts | BROWN UNIVERSITY | 2007-05-31 | — | — | US | disclosed |
| US-20070123715-A1 | Method of using rhodium quinonoid catalysts | BROWN UNIVERSITY | 2007-05-31 | — | — | US | disclosed |
| US-20070117981-A1 | Rhodium quinonoid catalysts | BROWN UNIVERSITY | 2007-05-24 | — | — | US | disclosed |
| US-20070117981-A1 | Rhodium quinonoid catalysts | BROWN UNIVERSITY | 2007-05-24 | — | — | US | disclosed |
| US-5384078-A | Reaction of dienes with epoxides and carbon dioxide to form lactones for reaction with calcium | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1995-01-24 | — | — | US | disclosed |
| US-5211889-A | Organocalcium cuprate complexes formed by reduction | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993003044-A1 | REACTIVE FORM OF CALCIUM AND REAGENTS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1993-02-18 | — | — | WO | disclosed |
| US-4434299-A | REACTION OF ALICYCLIC ALCOHOLS OR KETONES WITH AMMONIA | MOBIL OIL CORPORATION (US) | 1984-02-28 | — | — | US | disclosed |
| US-4379925-A | MOLYBDATE CATALYST | THE STANDARD OIL CO. (US) | 1983-04-12 | — | — | US | disclosed |
| US-4271091-A | OXIDES OF MOLYBDENUM, TUNGSTEN, VANADIUM AND/OR ANTIMONY | STANDARD OIL COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117981-A1 | Rhodium quinonoid catalysts | NQO2, NDUFV2, QARS1 | ESR2 1644/4885MAPT 3897/4885PDE4A 2623/4885 |
| US-20070123715-A1 | Method of using rhodium quinonoid catalysts | NQO2, NQO1, RECQL | ESR2 1317/4885MAPT 4481/4885PDE4A 4301/4885 |
| US-20150274663-A1 | S1P AND/OR ATX MODULATING AGENTS | LPAR3, S1PR3, S1PR1 | ESR2 1351/4885MAPT 4831/4885PDE4A 1784/4885 |
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ORMDL3, TALDO1, TAC3 | ESR2 1628/4885MAPT 4702/4885PDE4A 2663/4885 |
| US-20160229778-A1 | DIRECT B-ARYLATION OF CARBONYL COMPOUNDS | DBH, DDT, CBR3 | ESR2 960/4885MAPT 4423/4885PDE4A 2923/4885 |
| US-20210163514-A1 | COMPOUND OF 3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-BASED PHOSPHINE LIGAND, AND PREPARATION METHOD THEREOF | ORMDL3, TALDO1, TAC3 | ESR2 1708/4885MAPT 4698/4885PDE4A 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.